Shilpa Medicare Limiteds customer has received Fast Track Designation from the USFDA for an investigational drug candidate aimed at treating Glioblastoma, with clinical trials planned to begin soon. Shilpa is providing end-to-end development services for this drug, which is notable as no new drug for Glioblastoma has been approved in over two decades.